Tesamorelin 10mg + Ipamorelin 3mg
Strength: 13mg
CAS: Tesamorelin: 218949-48-5 / Ipamorelin: 170851-70-4
Chemical Formula: Tesamorelin: C₂₂₁H₃₆₆N₇₂O₆₇S Ipamorelin: C₃₈H₄₉N₉O₅
Molecular weight: Tesamorelin: 5136 g/mol Ipamorelin: 711.9 g/mol
Peptide Sequence: Tesamorelin: Trans-3-hexenoyl-Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu NH2 Ipamorelin: Aib-His-D-2Nal-D-Phe-Lys-NH₂
Synonyms: TH9507
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.
Tesamorelin 10mg + Ipamorelin 3mg is a fixed-ratio research peptide formulation from Novera Compounds supplied for qualified laboratory investigations. Its fixed composition provides both peptide components within one defined preparation for protocols that require simultaneous evaluation. Intended strictly for in vitro research ONLY. NOT for human use, clinical application, or human consumption.
Disclaimer : Available as lyophilized (freeze-dried) powder for laboratory and in vitro research applications. Reconstitution solution is not included in the pack.
Purity ≥99%
Made in USA
Research Use Only
Fast Shipping
Explore Other High-Purity Peptides
CJC-1295 - No DAC 10mg
$ 55.00
KPV 10mg
$ 70.00The Novera Compounds Advantage
Made in the USA
Manufactured in the United States under controlled standards. Reliable production. Dependable supply. No overseas uncertainty.
High Purity — 99% or Better
Every batch meets ≥99% purity specifications and is verified by independent third-party laboratory testing. Clean. Consistent. Documented.
Advanced Lyophilized Stability
Carefully lyophilized for structural integrity and easier handling. No cold shipping required. No dry ice. No complications.
Designed for Research
Ideal for scientific study, analytical testing, and research workflows where consistency and quality matter most.
Smart Pricing. Real Value.
High purity. USA-made. Third-party tested. Priced to make sense.
Everything in One Order
Already ordering other products? Add peptides to the same shipment. One vendor. One contact person. Simple.
Product Description
Specifications
Description
Strength: 13mg
CAS: Tesamorelin: 218949-48-5 / Ipamorelin: 170851-70-4
Chemical Formula: Tesamorelin: C₂₂₁H₃₆₆N₇₂O₆₇S Ipamorelin: C₃₈H₄₉N₉O₅
Molecular weight: Tesamorelin: 5136 g/mol Ipamorelin: 711.9 g/mol
Peptide Sequence: Tesamorelin: Trans-3-hexenoyl-Tyr Ala Asp Ala Ile Phe Thr Asn Ser Tyr Arg Lys Val Leu Gly Gln Leu Ser Ala Arg Lys Leu Leu Gln Asp Ile Met Ser Arg Gln Gln Gly Glu Ser Asn Gln Glu Arg Gly Ala Arg Ala Arg Leu NH2 Ipamorelin: Aib-His-D-2Nal-D-Phe-Lys-NH₂
Synonyms: TH9507
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.
Tesamorelin 10mg + Ipamorelin 3mg
Tesamorelin 10mg + Ipamorelin 3mg is a research peptide formulation supplied for qualified laboratory investigations. The fixed-ratio preparation combines tesamorelin and ipamorelin in a single lyophilized vial, allowing research teams to evaluate both peptide components within the same experimental framework when required by their study design. For qualified researchers looking to buy tesamorelin 10mg + ipamorelin 3mg blend for research, Direct Doctor Supply representatives can provide product information and sourcing guidance. This formulation is intended strictly for in vitro research only.
This product is intended strictly for in vitro research ONLY. It is NOT approved for human use, clinical application, or human consumption.
Research Product Specifications
| Product Detail | Specification |
| Strength | Tesamorelin 10mg + Ipamorelin 3mg |
| Active Compounds | Tesamorelin peptide + Ipamorelin peptide |
| Manufacturer | Novera Compounds |
| Brand | Novera |
| Country of Origin | United States |
| Form | Lyophilized powder |
| Classification | GHRH analog + GH secretagogue blend (GH-axis peptide stack) |
| Reconstitution | BAC water or sterile water |
| Intended Use | Research and in vitro studies only |
| Package | 1 vial |
| Weight | 5.7 gram |
The receiving laboratory decides working concentration, assay type, controls, and how the material’s use is captured in the study record.
When Does a Combined Peptide Formulation Fit a Research Protocol?
A combined tesamorelin and ipamorelin preparation is most relevant when a research protocol specifically requires both peptide components to be evaluated within the same experimental condition. In these situations, a fixed-ratio formulation may simplify preparation workflows by providing both materials in one defined research product rather than requiring separate peptide handling.
However, the combined vial is not intended to replace individual peptide materials in every research setting. When an investigation focuses on a single compound, separate reagents may provide greater control over individual experimental variables. The appropriate material depends on the scientific question, study design, and laboratory requirements.
Understanding the Roles of Tesamorelin and Ipamorelin Within the Formulation
The paired formulation contains two peptides that engage different components of the growth hormone axis. Tesamorelin provides the GHRH-related pathway component, while ipamorelin contributes the growth hormone secretagogue pathway through GHS-R1a activity.
Tesamorelin: GHRH-Receptor Component
Tesamorelin acts through the GHRH receptor pathway and contributes the receptor activity associated with growth hormone release studies.[1] Its FDA-approved history applies to tesamorelin as an individual compound and should not be interpreted as evidence for outcomes from the combined research formulation.
Ipamorelin: Ghrelin-Receptor Component
Ipamorelin provides the ghrelin-receptor component of the formulation through interaction with GHS-R1a. Its evidence base includes preclinical research and human clinical exposure, but these findings relate to ipamorelin as an individual compound rather than the combined preparation.[2][3]
Interpreting the Available Evidence for the Individual Peptides
The evidence available for tesamorelin and ipamorelin comes primarily from studies of the individual compounds rather than the combined formulation. Tesamorelin has an established FDA-approved single-agent history for a specific indication, while ipamorelin has preclinical evidence and Phase 2 clinical exposure without an approved therapeutic indication.[1][2][3]
The paired preparation itself has no controlled human trial or combined-formulation safety dataset. Findings observed in cell or animal models should therefore be interpreted within those specific research settings and not as evidence of a therapeutic effect in humans.
Research Applications and Laboratory Considerations
Research protocols involving this formulation may evaluate parameters such as receptor binding at the GHRH receptor and GHS-R1a, intracellular signaling responses including cAMP or calcium activity, GH release from pituitary cell models, and selectivity profiling against related pathways.
Whole-organism measurements such as visceral adipose tissue changes, lean mass, recovery, insulin sensitivity, glucose metabolism, and other metabolic markers belong to in vivo research settings involving individual compounds. These outcomes should not be presented as direct outputs of an in vitro study using the combined formulation.
Laboratories should maintain appropriate study records, including reconstitution medium, preparation details, working concentration, storage information, and protocol references to support research consistency.
Research-Only Status, Handling, and Regulatory Considerations
Tesamorelin 10mg + Ipamorelin 3mg is supplied exclusively as a research material and must remain within qualified laboratory environments. It is not intended to be injected, ingested, prescribed, self-administered, or used as a therapeutic product.
Handling should follow institutional procedures for research-use peptides, including appropriate storage, documentation, and disposal practices. Human safety information for the combined formulation has not been established. Tesamorelin and ipamorelin have separate evidence histories, but those records do not create a safety dataset for the paired preparation.[1][2]
The combined formulation has no therapeutic approval from the FDA, EMA, or other national regulatory agencies. Its regulatory status should be considered separately from the individual histories of each peptide, and institutions should verify applicable requirements before acquisition or research use.
Current as of September 2026.
Institutional Sourcing Considerations for Wholesale Research Supply
Institutional sourcing of a fixed-ratio peptide blend involves more than simply obtaining material. For research teams, documentation, lot consistency, and receiving procedures are important considerations when selecting a supplier and maintaining continuity throughout a study.
How Qualified Research Groups Buy Tesamorelin 10mg + Ipamorelin 3mg at Order Volume
When buying research peptides, laboratories typically evaluate factors such as certificate of analysis documentation, product identity records, and consistency between supplied lots. For studies conducted over several months, maintaining lot continuity can help reduce variability that may affect experimental comparisons.
Research groups exploring where to buy tesamorelin + ipamorelin blend online for institutional studies may consider suppliers that provide appropriate documentation and sourcing support. Receiving workflows commonly include reviewing purity information, identity records, and relevant batch documentation as part of laboratory quality procedures.
Shipping conditions are also an important consideration for lyophilized peptide materials. Receiving records may include shipment duration, temperature indicators where applicable, and the condition of the vial upon arrival to support proper documentation practices.
Institutions that buy peptide blend wholesale should also consider acquisition requirements, storage procedures, and internal research policies that apply to their location. Research programs may check for wholesale buying options that support consistent supply and batch continuity throughout the study period.
For those looking to buy tesamorelin + ipamorelin blend for research, Direct Doctor Supply representatives are available to provide product information and sourcing guidance.
What should a laboratory confirm before sourcing this blend?
The research team should first establish that the planned protocol requires both Tesamorelin and Ipamorelin in one preparation rather than either peptide individually.
Why would a research protocol require a combined formulation?
A combined research formulation may be appropriate when a study design requires both peptide components to be evaluated under the same experimental conditions. It provides researchers with one defined material format while maintaining the documentation requirements associated with the protocol.
What research role does tesamorelin represent in the blend?
Tesamorelin supplies the GHRH agonist component associated with growth hormone-releasing pathway research and visceral adipose tissue-related investigation.
What research function does ipamorelin provide within the formulation?
Ipamorelin supplies the growth hormone secretagogue component of the research formulation. Published evidence includes preclinical findings involving bone mineral content and body weight, while its postoperative-ileus Phase 2 program did not demonstrate efficacy on the primary endpoint. Controlled human studies have not established effects on lean mass or recovery.
Is there a standard Tesamorelin Ipamorelin blend dosage?
No standardized human dosage applies. Experimental quantities are determined by researchers according to their individual in vitro protocol.
What documentation should accompany research sourcing?
Relevant records can include product identity, preparation information, purity testing, certificate of analysis information, storage records, and institutional protocol documentation.
Is the formulation intended for people?
No. Intended strictly for in vitro research ONLY. NOT for human use, clinical application, or human consumption.
Citations
[1] U.S. Food and Drug Administration. “EGRIFTA (Tesamorelin for Injection) Prescribing Information.” AccessData, 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf
[2] Beck, David E et al. “Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” International journal of colorectal disease vol. 29,12 (2014): 1527-34. doi:10.1007/s00384-014-2030-8
[3] Svensson, J et al. “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.” The Journal of endocrinology vol. 165,3 (2000): 569-77. doi:10.1677/joe.0.1650569
Direct Doctor Supply sources its inventory only through authorized distribution channels, so every order arrives sealed in the manufacturer’s original packaging. Our sourcing standards and tracked delivery mean you receive authentic original products every time.
Content prepared by Direct Doctor Supply’s editorial team.
Sourcing and accuracy for this page follow our Editorial Policy: claims are cross-checked against clinical literature, regulatory filings, and manufacturer specifications before anything is published.



